The Global ENT
Disorder Treatment Market, by Treatment Type (Devices (Hearing Aid Devices,
Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type
(Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), By
Organ Type (Ear, Nose, and Throat), by End User (Hospitals, Clinics, Ambulatory
Surgical Centers, Home Care Settings, and Others), and by Region (North
America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was
valued at US$ 9,521.1 million in 2016 and is projected to exhibit a CAGR of
3.2% over the forecast period (2017–2025).
The ENT Disorders treatment
market is expected to gain significant traction with increasing incidence of
ENT disorders and increasing environmental pollution globally. According to an
article published by Harvard Medical School and Teaching Hospital, 2017, over
360 million people across the globe are suffering from hearing loss and over
half of this population can be treated with proper medication and care.
Development novel treatments for
ENT disorders through extensive R&D is expected to be a major factor
driving the global ENT disorder treatment market growth Manufacturers are
focusing on development new and innovative treatments and therapies for ENT
disorders for both adult and pediatric segments, in order to maintain their
market share. For instance, Otonomy, Inc. — a U.S. based drug manufacturer —
received FDA approval for OTIPRIO (ciproflaxin otic suspension) in December
2015, for treatment of pediatric patients suffering with bilateral otitis media
with effusion. Furthermore, in June 2017, Inspire Medical Systems received FDA
approval for Inspire 3028 neurostimulator for the treatment of obstructive
sleep apnea.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1326
In May 2012, Meda Pharmaceuticals
received FDA approval for dymista (azelastine hydrochloride and fluticasone
propionate) for the treatment of seasonal allergic rhinitis that can be
consumed by intranasal administration or sprayed suspension.
Key players are continuously
focusing on developing and updating their products with new technologies to
treat various types of disorders. Market players are conducting clinical trials
and a large number of treatment drugs and devices are in pipeline for
approvals. For instance, in February 2018, Tusker Medical announced their first
patient enrollment for pivotal clinical trial for tympanostomy tube replacement
that is performed for recurrent ear infections or persistent fluid in the
middle ear. Browse 42 Market Data Tables and 36 Figures spread through 161
Pages and in-depth TOC on “Global ENT Disorder Treatment Market”- by Treatment
Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing
Implants and Others) and Drug Type(Antibiotics, Antihistamines, Steroids,
Anti-inflammatory Drugs, Others)), By Organ Type (Ear, Nose and Throat), by End
User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings and
Others), and by Region (North America, Latin America, Europe, Asia Pacific, the
Middle East, and Africa) - Global Forecast to 2025
Key players are focusing on
strategic merger and acquisition strategies for development and
commercialization of novel ENT therapeutics and medical devices. For instance,
December 2017, Entellus Medical, Inc. — a leader in ENT drugs segment — entered
a definitive merger agreement with Stryker Corporation for development of
effective ENT solutions through collaboration. Moreover, in in July 2017,
Entellus Medical acquired Spirox, Inc. a privately held company that
manufactures, develops and markets ENT medical devices.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/ent-disorder-treatment-market-1326
Key Takeaways of the ENT Disorder
Treatment Market:
The global ENT disorder treatment
market is expected to exhibit a CAGR of 3.22% over the forecast period, owing
to rising incidence of ENT disorders coupled with deteriorating environmental
factors such as rising air and noise pollution across the globe. For instance,
according to CDC 2016, 30 million people in the U.S. were exposed to extremely
high decibels sound levels, at workplace, leading to hearing disorders.
Among treatment type segment,
drug segment holds a dominant position in the global ENT disorder treatment
market. This is owing to drug being the first line of treatment in most of the
ENT disorders.
Among end users, hospital segment
holds a dominant position in the global ENT disorder treatment market, as most
of the surgical, non-surgical as well as consultation procedures are conducted
at hospitals.
Some of the major players
operating in the global ENT disorder treatment market include Sanofi,
AstraZeneca plc, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical
Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck &
Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding
AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S,
Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone,
Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing
Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron
Hearing Inc., and Zounds Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1326
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment